Absin Bio的动态

Really an exciting news for medical science, although I believe it will take some years for the therapy to be available thought the world. ---------------------------------------------------------------------- Australian doctors' research on immunotherapy has dramatically improved outcomes for advanced melanoma patients globally. Half are now essentially cured, up from less than 10%. Read more: https://lnkd.in/ezwVsRUt

The first treatment of its kind for metastatic NSCLC, Optune Lua is approved for use concurrently with PD-1/PD-L1 inhibitors or docetaxel in adult patients with metastatic NSCLC who progressed on or after a platinum-based regimen. Results of the pivotal Phase 3 LUNAR trial represent the first substantial improvement in median overall survival in more than 8 years for this patient population. Optune Lua is a wearable treatment that delivers Tumor Treating Fields (TTFields), which exert physical forces on the electrically charged components of dividing cancer cells, resulting in cell death.

Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) chief scientific officer, Professor Lindy Durrant, talked with Proactive's Stephen Gunnion about the company's groundbreaking results from the SCOPE trial. The trial focuses on SCIB1 in combination with double checkpoint inhibitors ipilimumab and nivolumab for advanced melanoma. Professor Durrant highlighted that cohort one demonstrated an 84% disease control rate, with 72% of tumours shrinking and 20% completely clearing. The most exciting outcome was an 80% progression-free survival rate at six months, signalling durable and significant tumour control. This data underscores the potential for longer-term benefits in advanced cancer therapy. She emphasised the importance of progression-free survival as a predictor for overall survival and explained its role as the endpoint for upcoming phase two/three registration studies. The discussion also covered the next steps in the... Watch at #Proactive #ProactiveInvestors https://ow.ly/s8v1105PbBU

?? Whole-genome Mutational Analysis for Tumor-informed Detection of Circulating Tumor DNA in Patients with Urothelial Carcinoma #BladderCancer https://buff.ly/3xjbecQ

The first treatment of its kind for metastatic NSCLC, Optune Lua is approved for use concurrently with PD-1/PD-L1 inhibitors or docetaxel in adult patients with metastatic NSCLC who progressed on or after a platinum-based regimen. Results of the pivotal Phase 3 LUNAR trial represent the first substantial improvement in median overall survival in more than 8 years for this patient population. Optune Lua is a wearable treatment that delivers Tumor Treating Fields (TTFields), which exert physical forces on the electrically charged components of dividing cancer cells, resulting in cell death.

New nanosystem offers hope for improved diagnosis and treatment of tongue cancer A pioneering study has unveiled the Au-HN-1 nanosystem, a cutting-edge approach that promises to transform the diagnosis and treatment of tongue squamous cell carcinoma (TSCC). via News Medical Device / Technology News Feed

A combination treatment has translational potential in immunoresistant tumors! https://lnkd.in/eYNfmyeP Allison Joy Nielsen et al. show pharmacological inhibition of the DNA/protein kinase interaction induces sensitivity to immune checkpoint blockade in melanoma models.

ESMO 24: French phase III HypoG-01 trial (n= 1265) of BREAST cancer requiring nodal irradiation comparing 50 G/ 25 Fx (5 wk) to 40 Gy/ 15 Fx (3 wk) showed similar risks of toxicity including 5-year risk of arm lymphedema of about 33%, and similar 5-year range of shoulder motion impairment of about 20%.

Indoor tanning exposure, while known to increase risk of melanoma, may not be meaningfully associated with melanoma tumor mutational burden. https://ja.ma/4iyytT0